Eli Lilly LLY

NYS: LLY | ISIN: US5324571083   14/10/2026
1.208,74 USD (+3,62%)
(+3,62%)   14/10/2026
Grafiek Eli Lilly and Company Grafiek Eli Lilly and Company

Eli Lilly and Company in het nieuws

9 oktober 2026 · Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds · Persbericht

9 oktober 2026 · New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity · Persbericht

7 oktober 2026 · Nasdaq and S&P Hold Weekly Gains as Small Caps and Dow Slip Midweek · Persbericht

5 oktober 2026 · Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions · Persbericht

2 oktober 2026 · Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL · Persbericht

1 oktober 2026 · Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease · Persbericht

1 oktober 2026 · Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study · Persbericht

30 september 2026 · Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes · Persbericht

30 september 2026 · New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis · Persbericht

30 september 2026 · Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes · Persbericht

Profiel Eli Lilly and Company

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.lilly.com

Hoofdzetel: Indianapolis, Indiana vlag Verenigde Staten

Mijn selecties